Demographic information for the civilian workers and the subgroup of Marines/Navy personnel is provided in Tables 1 and 2. Tables providing demographic information and all statistical results for the Camp Pendleton and Camp Lejeune full cohort of Marines/Navy personnel are included in Supplemental file, Tables S1 to S4.
The Marines/Navy personnel in the Camp Lejeune and Camp Pendleton subgroup generally appeared similar on sex, rank, age, length of follow-up and the percent of the cohort that died. There appeared to be small differences in attained education level and race. The combined subgroup was mostly male (95.7%), white (75.6%) and ranged in rank from E1 to E4 (81.7%). Of note was that about 2% were above the age of 65 years at the end of follow-up. The average length of follow-up was about 36 years, and the total amount of person-years was 11,839,529. About 12% of the Marines/Navy personnel in the subgroup had died by the end of follow-up.
Among the Camp Lejeune and Camp Pendleton civilian workers, the percentages of women were 49.4% and 45.4%, respectively. Most of the Camp Lejeune and Camp Pendleton civilian workers were White. A much higher percentage of the Camp Lejeune workforce was African American (19.2%) compared to Camp Pendleton (7.5%). A higher percentage at Camp Lejeune graduated from college (14.8%) compared to Camp Pendleton (6.9%). Over half of the civilian workers in the study were above 70 years of age at the end of follow-up. The average length of follow-up was about 31 years, and the total amount of person-years was 434,965. About 42% (N = 3,055) of the Camp Lejeune civilian workers and 49% (N = 3,280) of Camp Pendleton civilian workers had died by the end of follow-up.
The results of the SMR and Poisson regression analyses for the Camp Lejeune and Camp Pendleton Marines/Navy personnel subgroup are shown in Table 3. The SMRs for most of the underlying causes of death, including death from all causes and all cancer malignancies, were less than 1.00, consistent with a “healthy veteran effect” [16–18]. The healthy veteran effect could be due to several factors including the initial physical screening for healthy recruits, physical fitness standards during military service, and access to quality health care during and after service. The healthy veteran effect may have been especially strong in this relatively young subgroup: at the end of follow-up about 98% were less than 65 years of age and about 43% were less than 55 years of age. SMRs above 1.00 at Camp Lejeune were observed for cancers of the esophagus, pancreas, cervix, prostate, kidney, connective tissue, and Parkinson disease, amyotrophic lateral sclerosis (ALS) and suicide. SMRs above 1.00 at Camp Pendleton were observed for cancers of the uterus, male breast, prostate, thyroid, and for alcoholism, ALS, and suicide.
Table 3
Standardized mortality ratios (SMR), Poisson regression risk ratios, and 95% confidence intervals (CI) for the Camp Lejeune and Camp Pendleton Marines/Navy personnel subgroup: Underlying cause of death
Cause of Death | Camp Lejeune (CL) | Camp Pendleton (CP) | Risk Ratio (95% CI) |
| Observed SMR (95% CI) | Observed SMR (95% CI) | CL vs CP |
All Causes | 19,250 0.90 (0.89, 0.91) | 21,134 0.93 (0.92, 0.94) | 0.99 (0.97, 1.01) |
All Cancer Malignancies | 3,689 0.92 (0.89, 0.95) | 3,760 0.87 (0.84, 0.90) | 1.07 (1.02, 1.12) |
Oral Cavity and Pharynx | 106 0.85 (0.70, 1.03) | 124 0.92 (0.77, 1.10) | 0.95 (0.73, 1.23) |
Esophagus | 171 1.01 (0.87, 1.18) | 154 0.83 (0.70, 0.97) | 1.25 (1.00, 1.55) |
Stomach | 89 0.78 (0.62, 0.95) | 100 0.83 (0.68, 1.01) | 0.93 (0.70, 1.24) |
Colon | 266 0.87 (0.77, 0.98) | 264 0.81 (0.71, 0.91) | 1.07 (0.91, 1.27) |
Rectum | 83 0.79 (0.63, 0.98) | 94 0.83 (0.67, 1.02) | 0.93 (0.69, 1.26) |
Liver/Biliary System | 268 0.84 (0.75, 0.95) | 289 0.85 (0.76, 0.96) | 1.01 (0.86, 1.20) |
Pancreas | 265 1.06 (0.94, 1.19) | 250 0.92 (0.81, 1.04) | 1.15 (0.97, 1.37) |
Larynx | 36 0.76 (0.53, 1.06) | 39 0.77 (0.55, 1.05) | 1.04 (0.66, 1.64) |
Lung/Trachea/Bronchus | 982 0.97 (0.91, 1.03) | 915 0.83 (0.78, 0.89) | 1.19 (1.08, 1.30) |
Connective Tissue | 53 1.03 (0.77, 1.34) | 50 0.90 (0.67, 1.19) | 1.17 (0.80, 1.73) |
Melanoma | 105 0.98 (0.80, 1.18) | 109 0.89 (0.73, 1.07) | 1.09 (0.84, 1.43) |
Breast Cancer - Female | 41 0.92 (0.66, 1.25) | 25 0.72 (0.47, 1.07) | 1.23 (0.75, 2.03) |
Breast Cancer - Male | 4 0.69 (0.19, 1.75) | 11 1.76 (0.88, 3.15) | 0.39 (0.12, 1.22) |
Cervix | 9 1.07 (0.49, 2.03) | 5 0.79 (0.26, 1.85) | 1.21 (0.39, 3.72) |
Uterus | 5 0.91 (0.30, 2.12) | 7 1.59 (0.64, 3.28) | 0.59 (0.19, 1.88) |
Ovary | 8 0.72 (0.31, 1.42) | 6 0.67 (0.24, 1.45) | 1.19 (0.41, 3.44) |
Prostate | 95 1.01 (0.81, 1.23) | 108 1.06 (0.87, 1.28) | 0.94 (0.71, 1.24) |
Testis | 18 0.72 (0.42, 1.15) | 12 0.45 (0.23, 0.79) | 1.72 (0.83, 3.58) |
Kidney and Renal Pelvis | 139 1.11 (0.93, 1.31) | 126 0.91 (0.76, 1.09) | 1.21 (0.95, 1.54) |
Urinary Bladder | 61 0.97 (0.74, 1.24) | 66 0.94 (0.73, 1.20) | 1.02 (0.72, 1.45) |
Brain and CNS | 178 0.91 (0.78, 1.06) | 217 1.00 (0.87, 1.15) | 0.90 (0.74, 1.10) |
Thyroid | 8 0.78 (0.34, 1.55) | 12 1.07 (0.55, 1.88) | 0.72 (0.30, 1.77) |
Hematopoietic Cancers | 354 0.83 (0.75, 0.92) | 380 0.83 (0.74, 0.91) | 1.00 (0.87, 1.16) |
Hodgkin Lymphoma | 30 0.93 (0.63, 1.32) | 32 0.91 (0.62, 1.29) | 1.00 (0.61, 1.65) |
NHL | 122 0.73 (0.60, 0.87) | 151 0.83 (0.70, 0.97) | 0.87 (0.68, 1.10) |
Multiple Myeloma | 62 0.99 (0.77, 1.26) | 61 0.92 (0.70, 1.18) | 1.08 (0.76, 1.54) |
Leukemias | 142 0.87 (0.73, 1.02) | 136 0.77 (0.65, 0.91) | 1.13 (0.89, 1.43) |
Diabetes | 400 0.71 (0.64, 0.78) | 452 0.75 (0.69, 0.83) | 0.94 (0.82, 1.08) |
Alcoholism | 242 0.93 (0.81, 1.05) | 302 1.07 (0.95, 1.20) | 0.88 (0.74, 1.04) |
Multiple Sclerosis | 29 0.78 (0.52, 1.12) | 27 0.68 (0.45, 0.99) | 1.12 (0.66, 1.89) |
Parkinson Disease | 15 1.47 (0.73, 2.21) | 8 0.69 (0.21, 1.17) | 2.00 (0.85, 4.73) |
ALS | 64 1.12 (0.85, 1.39) | 67 1.05 (0.80, 1.30) | 1.05 (0.75, 1.48) |
Cardiovascular Disease | 4,316 0.90 (0.87, 0.93) | 4,650 0.91 (0.88, 0.94) | 1.00 (0.96, 1.04) |
COPD | 312 0.96 (0.86, 1.07) | 320 0.89 (0.79, 0.99) | 1.10 (0.94, 1.28) |
Chronic Liver Disease | 614 0.79 (0.73, 0.86) | 775 0.91 (0.84, 0.97) | 0.88 (0.79, 0.97) |
Cause of Death | Camp Lejeune (CL) | Camp Pendleton (CP) | Risk Ratio (95% CI) |
| Observed SMR (95% CI) | Observed SMR (95% CI) | CL vs CP |
Chronic Kidney Disease | 133 0.62 (0.52, 0.74) | 139 0.64 (0.54, 0.75) | 0.99 (0.78, 1.25) |
Suicide | 1,664 1.21 (1.16, 1.27) | 2,002 1.32 (1.27, 1.38) | 0.92 (0.86, 0.98) |
CNS: central nervous system |
NHL: non-Hodgkin lymphoma |
ALS: amyotrophic lateral sclerosis |
COPD: chronic obstructive pulmonary disease |
SMRs were calculated using the age-, sex-, race- and calendar period-specific U.S. mortality rates for underlying causes of death. |
Risk ratios were adjusted for sex, race, and five-year age groups. |
In the Poisson regression analyses of underlying cause of death comparing the Camp Lejeune and Camp Pendleton Marines/Navy personnel subgroup, risk ratios (RRs) ≥ 1.20 with CIRs ≤ 3 were observed for cancers of the esophagus (RR = 1.25, 95% CI: 1.00, 1.55), and kidney (RR = 1.21, 95% CI: 0.95, 1.54). Female breast cancer had a RR of 1.23 with CIR ≤ 3 (95% CI: 0.75, 2.03). A few other causes of death with RRs ≥ 1.20 but with CIRs > 3 included cancers of the cervix and testes and Parkinson disease.
The results of the SMR and Poisson regression analyses for the Camp Lejeune and Camp Pendleton civilian workers are presented in Table 4. The SMRs for most of the causes of death, including deaths from all causes and all cancer malignancies, were less than 1.00. These findings indicated the impact of the “healthy worker effect” [19]. In the Poisson regression analyses comparing Camp Lejeune versus Camp Pendleton civilian workers, RRs ≥ 1.20 with CIRs ≤ 3 were observed for female breast cancer (RR = 1.21, 95% CI: 0.77, 1.89) and chronic kidney disease (RR = 1.77, 95% CI: 1.07, 2.93). A few other causes of death had RRs ≥ 1.20 but with CIRs > 3 and included cancers of the kidney, pharynx, and larynx, and melanoma, Hodgkin lymphoma, and anemias.
Table 4
Standardized mortality ratios (SMRs) and Poisson regression risk ratios for the Camp Lejeune and Camp Pendleton civilian workers: Underlying cause of death
Cause of Death | CL | CP | Risk Ratio (95% CI) |
| Observed SMR (95% CI) | Observed SMR (95% CI) | CL vs CP |
All causes | 3,055 0.89 (0.85, 0.92) | 3,280 0.90 (0.87, 0.94) | 0.96 (0.91, 1.01) |
All cancers | 882 0.93 (0.87, 0.99) | 890 0.93 (0.87, 0.99) | 1.01 (0.92, 1.12) |
All malignant cancers | 859 0.91 (0.85, 0.98) | 874 0.91 (0.85, 0.98) | 1.01 (0.91, 1.11) |
Oral cavity and pharynx | 10 0.62 (0.31, 1.10) | 10 0.62 (0.31, 1.10) | 1.06 (0.43, 2.61) |
Pharynx | 8 0.95 (0.41, 1.88) | 4 0.48 (0.13, 1.24) | 2.14 (0.61, 7.46) |
Esophagus | 13 0.51 (0.27, 0.88) | 24 0.96 (0.61, 1.43) | 0.63 (0.31, 1.27) |
Stomach | 21 0.85 (0.53, 1.30) | 21 0.87 (0.54, 1.33) | 1.00 (0.53, 1.90) |
Colon | 46 0.61 (0.45, 0.82) | 55 0.70 (0.53, 0.92) | 0.85 (0.56, 1.29) |
Rectum | 13 0.87 (0.46, 1.48) | 14 0.92 (0.50, 1.54) | 0.95 (0.43, 2.08) |
Liver/Biliary system | 20 0.62 (0.38, 0.96) | 29 0.92 (0.62, 1.32) | 0.73 (0.40, 1.32) |
Pancreas | 41 0.78 (0.56, 1.06) | 63 1.20 (0.92, 1.53) | 0.72 (0.48, 1.08) |
Larynx | 8 0.94 (0.41, 1.86) | 5 0.59 (0.19, 1.38) | 1.36 (0.42, 4.40) |
Lung | 310 1.08 (0.96, 1.20) | 281 0.96 (0.85, 1.08) | 1.15 (0.97, 1.36) |
Kidney and renal pelvis | 24 1.16 (0.74, 1.73) | 15 0.70 (0.39, 1.16) | 1.49 (0.76, 2.92) |
Urinary bladder | 18 0.85 (0.50, 1.34) | 25 1.06 (0.69, 1.57) | 0.65 (0.34, 1.24) |
Melanoma | 12 1.03 (0.53, 1.80) | 5 0.41 (0.13, 0.97) | 2.59 (0.89, 7.56) |
Connective tissue | 5 0.90 (0.29, 2.11) | 6 1.10 (0.40, 2.40) | 0.65 (0.19, 2.22) |
Brain and CNS | 17 0.87 (0.50, 1.39) | 28 1.44 (0.96, 2.09) | 0.66 (0.36, 1.23) |
Thyroid | 1 | 0 | |
Hematopoietic cancers | 84 1.00 (0.80, 1.24) | 90 1.02 (0.82, 1.25) | 1.00 (0.73, 1.36) |
Hodgkin lymphoma | 3 1.47 (0.30, 4.29) | 2 0.98 (0.12, 3.55) | 1.81 (0.30, 11.0) |
NHL | 35 1.12 (0.78, 1.56) | 38 1.13 (0.80, 1.55) | 0.98 (0.61, 1.58) |
Multiple myeloma | 15 0.79 (0.44, 1.30) | 13 0.68 (0.36, 1.16) | 0.99 (0.45, 2.16) |
Leukemias | 31 0.98 (0.67, 1.39) | 37 1.11 (0.78, 1.53) | 1.00 (0.61, 1.64) |
Breast cancer - Female | 48 0.84 (0.62, 1.12) | 33 0.63 (0.44, 0.89) | 1.21 (0.77, 1.89) |
Breast cancer - Male | 0 | 0 | |
Cervix | 1 | 3 0.55 (0.11, 1.60) | |
Uterus | 10 1.01 (0.49, 1.87) | 9 1.00 (0.46, 1.90) | 0.97 (0.39, 2.43) |
Ovary | 14 0.75 (0.41, 1.26) | 22 1.28 (0.80, 1.94) | 0.57 (0.29, 1.13) |
Prostate | 71 0.99 (0.78, 1.25) | 59 0.80 (0.61, 1.04) | 1.01 (0.69, 1.50) |
Testis | 0 | 0 | |
Diabetes | 94 0.90 (0.72, 1.10) | 103 0.98 (0.80, 1.19) | 0.78 (0.58, 1.05) |
Alcoholism | 7 0.56 (0.23, 1.16) | 10 0.87 (0.42, 1.61) | 0.63 (0.23, 1.74) |
Multiple sclerosis | 3 0.63 (0.13, 1.85) | 3 0.73 (0.15, 2.12) | 0.70 (0.14, 3.52) |
Parkinson disease | 30 1.34 (0.86, 1.82) | 31 1.19 (0.77, 1.60) | 1.15 (0.68, 1.93) |
ALS | 5 0.57 (0.07, 1.07) | 10 1.12 (0.43, 1.82) | 0.44 (0.14, 1.32) |
Anemias | 7 1.20 (0.48, 2.47) | 3 0.48 (0.10, 1.41) | 1.61 (0.39, 6.61) |
Cause of Death | CL | CP | Risk Ratio (95% CI) |
| Observed SMR (95% CI) | Observed SMR (95% CI) | CL vs CP |
Heart/Circulatory disease | 1105 0.88 (0.83, 0.93) | 1271 0.93 (0.88, 0.98) | 0.92 (0.85, 1.00) |
COPD | 171 0.99 (0.85, 1.15) | 213 1.13 (0.99, 1.30) | 0.91 (0.73, 1.11) |
Chronic liver disease | 36 0.70 (0.49, 0.97) | 51 1.04 (0.77, 1.36) | 0.71 (0.46, 1.10) |
Chronic kidney disease | 49 0.84 (0.62, 1.11) | 26 0.43 (0.28, 0.63) | 1.77 (1.07, 2.93) |
Suicide | 29 0.84 (0.56, 1.21) | 45 1.36 (0.99, 1.82) | 0.68 (0.42, 1.10) |
CL: Camp Lejeune |
CP: Camp Pendleton |
SMR: Standardized mortality ratio |
CI: Confidence interval |
CNS: Central nervous system cancers |
NHL: Non-Hodgkin lymphoma |
ALS: Amyotrophic Lateral Sclerosis |
COPD: Chronic obstructive pulmonary disease |
SMRs were calculated using the age-, sex-, race- and calendar period-specific U.S. mortality rates for underlying causes of death. |
Risk ratios were adjusted for sex, race, and five-year age groups. |
The unadjusted and adjusted HRs for underlying cause of death from the Cox proportional hazards regressions comparing the Camp Lejeune and Camp Pendleton Marines/Navy personnel subgroup are shown in Table 5. The adjusted HR for all cancer malignancies was 1.05 (95% CI: 1.02, 1.08). Adjusted HRs ≥ 1.20 with CIRs ≤ 3 were observed for cancers of the kidney (HR = 1.21, 95% CI: 0.95, 1.54), esophagus (HR = 1.24, 95% CI: 1.00, 1.54), and female breast cancer (HR = 1.20, 95% CI: 0.73, 1.98). HRs ≥ 1.20 with CIRs > 3 included Parkinson disease, myelodysplastic syndrome, and cancers of the testes, cervix, and ovary.
Table 5
Hazard ratios (HR) and 95% confidence intervals (CI) for the Marines/Navy personnel subgroup analysis of base location at Camp Lejeune (CL) vs. Camp Pendleton (CP); Underlying cause of death
Outcome | Total | Camp Lejeune # | Unadjusted HR (95% CI) | Adjusted HR (95% CI) | Camp Pendleton # |
All causes | 40,384 | 19,250 | 0.98(0.96, 1.00) | 0.99(0.97, 1.01) | 21,134 |
All cancer malignancies | 7,449 | 3,689 | 1.06(1.01, 1.11) | 1.06(1.02, 1.11) | 3,760 |
Oral cancers | 230 | 106 | 0.92(0.71, 1.19) | 0.95(0.73, 1.24) | 124 |
Pharyngeal cancer | 121 | 56 | 0.93(0.65, 1.33) | 0.94(0.66, 1.35) | 65 |
Esophageal cancer | 325 | 171 | 1.20(0.97, 1.49) | 1.24 (1.00, 1.54) | 154 |
Stomach cancers | 189 | 89 | 0.96(0.72, 1.28) | 0.92(0.69, 1.23) | 100 |
Colorectal cancers | 707 | 349 | 1.05(0.91, 1.22) | 1.03(0.88, 1.19) | 358 |
Colon cancer | 530 | 266 | 1.09(0.92, 1.29) | 1.05(0.89, 1.25) | 264 |
Rectal cancer | 177 | 83 | 0.95(0.71, 1.27) | 0.94(0.70, 1.27) | 94 |
Liver cancer | 557 | 268 | 1.00(0.85, 1.19) | 1.06(0.89, 1.25) | 289 |
Pancreatic cancer | 515 | 265 | 1.14(0.96, 1.36) | 1.14(0.96, 1.36) | 250 |
Laryngeal cancer | 75 | 36 | 1.00(0.64, 1.57) | 1.01(0.64, 1.58) | 39 |
Lung cancer | 1,897 | 982 | 1.16(1.06, 1.27) | 1.18(1.07, 1.29) | 915 |
Bone cancers | 40 | 16 | 0.71(0.38, 1.34) | 0.74(0.39, 1.39) | 24 |
Soft tissue cancers | 103 | 53 | 1.14(0.77, 1.67) | 1.12(0.76, 1.65) | 50 |
Melanoma | 214 | 105 | 1.03(0.79, 1.35) | 1.07(0.82, 1.40) | 109 |
Female Breast cancer | 66 | 41 | 1.27(0.77, 2.08) | 1.20 (0.73, 1.98) | 25 |
Male Breast cancer | 15 | 4 | 0.39(0.13, 1.24) | 0.36 (0.12, 1.14) | 11 |
Cervical cancer | 14 | 9 | 1.19(0.39, 3.65) | 1.25 (0.40, 3.85) | 5 |
Uterine cancer | 12 | 5 | 0.62(0.20, 1.97) | 0.62 (0.20, 1.98) | 7 |
Ovarian cancer | 14 | 8 | 1.12(0.39, 3.24) | 1.23 (0.42, 3.59) | 6 |
Prostate cancer | 203 | 95 | 0.97(0.74, 1.28) | 0.93 (0.71, 1.23) | 108 |
Testicular cancer | 30 | 18 | 1.62(0.78, 3.36) | 1.76 (0.85, 3.67) | 12 |
Bladder cancer | 127 | 61 | 1.00(0.71, 1.42) | 1.02(0.72, 1.45) | 66 |
Kidney cancer | 265 | 139 | 1.19(0.93, 1.51) | 1.21(0.95, 1.54) | 126 |
Brain and CNS cancers | 395 | 178 | 0.88(0.72, 1.07) | 0.89(0.73, 1.09) | 217 |
Thyroid cancer | 20 | 8 | 0.71(0.29, 1.74) | 0.71(0.29, 1.74) | 12 |
Hematopoietic cancers | 734 | 354 | 1.00(0.86, 1.16) | 0.99(0.86, 1.14) | 380 |
Hodgkin lymphoma | 62 | 30 | 1.00(0.61, 1.64) | 0.98(0.59, 1.61) | 32 |
Non-Hodgkin lymphoma | 273 | 122 | 0.87(0.68, 1.10) | 0.87(0.68, 1.10) | 151 |
Multiple myeloma | 123 | 62 | 1.10(0.77, 1.56) | 1.07(0.75, 1.53) | 61 |
Leukemias | 278 | 142 | 1.12(0.89, 1.42) | 1.10(0.87, 1.40) | 136 |
ALL | 45 | 20 | 0.85(0.47, 1.53) | 0.85(0.47, 1.53) | 25 |
CLL | 15 | 7 | 0.94(0.34, 2.59) | 0.89(0.32, 2.48) | 8 |
AML | 122 | 62 | 1.12(0.78, 1.59) | 1.11(0.78, 1.59) | 60 |
CML | 28 | 11 | 0.69(0.32, 1.47) | 0.65(0.30, 1.40) | 17 |
MDS | 17 | 11 | 1.96(0.73, 5.30) | 2.26(0.83, 6.17) | 6 |
Outcome | Total | Camp Lejeune # | Unadjusted HR (95%CI) | Adjusted HR (95% CI) | Camp Pendleton # |
Lymphoid cancers | 63 | 27 | 0.82(0.50, 1.35) | 0.80(0.49, 1.33) | 36 |
Myeloid cancers | 157 | 79 | 1.12(0.82, 1.53) | 1.10(0.80, 1.50) | 78 |
Diabetes | 852 | 400 | 0.96(0.84, 1.10) | 0.96(0.83, 1.09) | 452 |
Anemias | 25 | 12 | 1.00(0.46, 2.19) | 0.89(0.41, 1.97) | 13 |
Cardiovascular disease | 8,966 | 4,316 | 1.00(0.96, 1.04) | 0.99(0.95, 1.03) | 4,650 |
Heart disease | 7,331 | 3,512 | 0.99(0.95, 1.04) | 0.99(0.94, 1.03) | 3,819 |
Stroke | 861 | 432 | 1.08(0.95, 1.24) | 1.05(0.92, 1.20) | 429 |
Circulatory diseases | 773 | 371 | 0.99(0.86, 1.14) | 0.95(0.82, 1.09) | 402 |
COPD | 632 | 312 | 1.06(0.91, 1.24) | 1.08(0.93, 1.27) | 320 |
Chronic Liver disease | 1,389 | 614 | 0.85(0.77, 0.95) | 0.93(0.83, 1.03) | 775 |
Cirrhosis | 1,560 | 693 | 0.86(0.78, 0.95) | 0.93(0.84, 1.03) | 867 |
Alcoholic Liver disease | 901 | 381 | 0.79(0.69, 0.90) | 0.86(0.76, 0.99) | 520 |
Nonalcoholic Liver disease | 488 | 233 | 0.98(0.82, 1.17) | 1.06(0.89, 1.27) | 255 |
Acute Kidney disease | 42 | 18 | 0.81(0.44, 1.50) | 0.81(0.44, 1.50) | 24 |
Chronic Kidney disease | 272 | 133 | 1.03(0.82, 1.31) | 0.96(0.75, 1.22) | 139 |
Parkinson disease | 23 | 15 | 2.09(0.89, 4.94) | 2.05(0.86, 4.87) | 8 |
ALS | 131 | 64 | 1.03(0.73, 1.45) | 1.04(0.73, 1.46) | 67 |
Multiple sclerosis | 56 | 29 | 1.18(0.70, 1.99) | 1.18(0.70, 2.00) | 27 |
Alcoholism | 544 | 242 | 0.86(0.72, 1.02) | 0.90(0.76, 1.07) | 302 |
Suicide | 3,666 | 1,664 | 0.88(0.83, 0.94) | 0.93(0.87, 0.99) | 2,002 |
CL = 159,128 Males = 151,026 Females = 8,102 |
CP = 168,406 Males = 162,473 Females = 5,933 |
Total = 327,534 Males = 313,499 Females = 14,035 |
COPD: chronic obstructive pulmonary disease |
ALS: amyotrophic lateral sclerosis |
MDS: myelodysplastic syndrome |
CML: chronic myeloid leukemia |
AML: acute myeloid leukemia |
CLL: chronic lymphocytic leukemia |
ALL: acute lymphocytic leukema |
CNS: central nervous system |
HRs adjusted for sex, race, rank and education level; age was the time variable. |
In the analyses of the full cohort of Marines/Navy personnel, in addition to causes listed above, additional underlying causes of death with adjusted HRs ≥ 1.20 and CIRs ≤ 3 included acute myeloid leukemia (HR = 1.21, 95% CI: 0.94, 1.56), Hodgkin lymphoma (HR = 1.25, 95% CI: 0.82, 1.90), multiple sclerosis (HR = 1.37, 95% CI: 0.92, 2.06) and acute kidney disease (HR = 1.32, 95% CI: 0.91, 1.90) (Supplemental file, Table S3).
Evaluation of contributing causes of death in the Marines/Navy personnel subgroup, comparing Camp Lejeune with Camp Pendleton, is presented in (Supplemental file, Table S5).. The findings were generally similar to the subgroup analyses of underlying causes from Table 5, with no additional causes of death having HRs ≥ 1.20 and CIRs ≤ 3 except for multiple sclerosis (HR = 1.29, 95% CI: 0.83, 2.01). Evaluation of contributing causes of death in the full cohort of Marines/Navy personnel observed an HR for male breast cancer of 1.27 but with CIR > 3 (95% CI: 0.61, 2.64) (Supplemental file, Table S4).
Analysis of the Marines/Navy personnel subgroup, for underlying cause of death and duration stationed between 1975 and 1985 at Camp Lejeune compared with Camp Pendleton as the reference group is presented in (Supplemental file, Table S6). The categorical levels of duration were approximately tertiles of the data after removal of the reference group. Since the DMDC data is quarterly, the levels of the categorical variable consisted of the number of quarters the individual was stationed at Camp Lejeune: “low” duration (1–2 quarters), “medium” duration (> 2–7 quarters), and “high” duration (> 7 quarters). A monotonic trend was observed for myelodysplastic syndrome, with the adjusted HR ranging from 1.77 (95% CI: 0.44, 7.11) in the low duration to 3.11 (95% CI: 0.86, 11.20) in the high duration strata. CIRs at all durations were > 3. Other underlying causes of death with monotonic trends were non-alcoholic liver disease (low duration HR = 1.03, 95% CI: 0.79, 1.34); high duration HR = 1.18, 95% CI: 0.81, 1.52) and pancreatic cancer (low duration HR = 1.11, 95% CI: 0.86, 1.43; high duration HR = 1.15, 95% CI: 1.01, 1.30), both with CIRs ≤ 3.
The unadjusted and adjusted HRs from the Cox proportional hazards regressions for underlying cause of death comparing the Camp Lejeune versus Camp Pendleton civilian workers are shown in Table 6. Adjusted HRs ≥ 1.20 with CIRs ≤ 3 were observed for chronic kidney disease (HR = 1.88, 95% CI: 1.13, 3.11) and Parkinson disease (HR = 1.21, 95% CI: 0.72, 2.04). An HR of 1.19 was observed for female breast cancer (95% CI: 0.76, 1.88). Other underlying causes of death with HRs ≥ 1.20 but with CIRs > 3 included cancers of the kidney and pharynx, melanoma, Hodgkin lymphoma, chronic myeloid leukemia (CML), and anemias.
Table 6
Comparison of Camp Lejeune (CL) and Camp Pendleton (CP) civilian workers: Underlying cause of death
Outcome | Total | Camp Lejeune # | Unadjusted HR (95% CI) | Adjusted HR (95% CI) | Camp Pendleton # |
All causes | 6,335 | 3,055 | 0.96 (0.91, 1.01) | 0.96(0.91, 1.01) | 3,280 |
All cancers | 1,772 | 882 | 0.99(0.91, 1.09) | 1.00(0.91, 1.11) | 890 |
All malignancies | 1,733 | 859 | 0.98(0.90, 1.08) | 1.00(0.91, 1.10) | 874 |
Oral cancers | 20 | 10 | 1.00(0.42, 2.41) | 1.03(0.41, 2.58) | 10 |
Pharynx | 12 | 8 | 2.02(0.61, 6.71) | 2.21(0.63, 7.78) | 4 |
Esophagus | 37 | 13 | 0.54(0.28, 1.07) | 0.63(0.31, 1.28) | 24 |
Stomach | 42 | 21 | 0.98(0.53, 1.79) | 0.92(0.48, 1.76) | 21 |
Colorectal cancers | 126 | 58 | 0.86(0.61, 1.23) | 0.86(0.59, 1.24) | 68 |
Colon | 101 | 46 | 0.85(0.57, 1.26) | 0.85(0.56, 1.28) | 55 |
Rectum and Rectosigmoid junction | 27 | 13 | 0.93(0.43, 1.97) | 0.95(0.43, 2.09) | 14 |
Rectum only | 17 | 8 | 0.87(0.34, 2.27) | 0.84(0.31, 2.27) | 9 |
Liver, biliary, gall bladder | 49 | 20 | 0.71(0.40, 1.25) | 0.77(0.43, 1.39) | 29 |
Liver and bile ducts | 38 | 16 | 0.75(0.39, 1.43) | 0.80(0.41, 1.57) | 22 |
Primary liver | 15 | 6 | 0.68(0.24, 1.92) | 0.87(0.31, 2.48) | 9 |
Pancreas | 104 | 41 | 0.64(0.43, 0.95) | 0.71(0.47, 1.06) | 63 |
Larynx | 13 | 8 | 1.52(0.50, 4.67) | 1.19(0.37, 3.83) | 5 |
Lung | 591 | 310 | 1.10(0.94, 1.30) | 1.13(0.96, 1.34) | 281 |
Urinary bladder | 43 | 18 | 0.78(0.43, 1.43) | 0.65(0.34, 1.26) | 25 |
Kidney | 39 | 24 | 1.56(0.82, 2.98) | 1.44(0.73, 2.84) | 15 |
Brain and CNS | 45 | 17 | 0.58(0.32, 1.07) | 0.61(0.33, 1.13) | 28 |
Connective tissue | 11 | 5 | 0.81(0.25, 2.65) | 0.60(0.17, 2.14) | 6 |
Melanoma | 17 | 12 | 2.42(0.85, 6.89) | 3.03(1.05, 8.76) | 5 |
Hematopoietic cancers | 174 | 84 | 0.95(0.70, 1.28) | 1.00(0.73, 1.36) | 90 |
Lymphoid cancers | 17 | 6 | 0.57(0.21, 1.53) | 0.84(0.30, 2.34) | 11 |
Myeloid cancers | 40 | 19 | 0.89(0.48, 1.66) | 0.98(0.51, 1.88) | 21 |
Hodgkin lymphoma | 5 | 3 | 1.48(0.25, 8.86) | 1.65(0.27, 9.96) | 2 |
Non-Hodgkin lymphoma | 73 | 35 | 0.97(0.61, 1.53) | 0.95(0.59, 1.54) | 38 |
Multiple myeloma | 28 | 15 | 1.11(0.53, 2.33) | 1.02 (0.47, 2.24) | 13 |
Leukemias | 68 | 31 | 0.85(0.53, 1.37) | 1.00(0.61, 1.64) | 37 |
CLL | 13 | 5 | 0.68(0.22. 2.09) | 0.85(0.27, 2.63) | 8 |
AML | 31 | 15 | 0.93(0.46, 1.88) | 0.97(0.47, 2.02) | 16 |
CML | 8 | 4 | 0.99(0.25, 3.96) | 1.26(0.29, 5.48) | 4 |
Female Breast | 81 | 48 | 1.24 (0.79, 1.93) | 1.19 (0.76, 1.88) | 33 |
Uterus | 19 | 10 | 1.00 (0.41, 2.48) | 0.99 (0.39, 2.49) | 9 |
Ovary | 36 | 14 | 0.58 (0.29, 1.13) | 0.60 (0.30, 1.19) | 22 |
Prostate | 130 | 71 | 1.32 (0.93, 1.86) | 1.03 (0.71, 1.51) | 59 |
Diabetes | 197 | 94 | 0.94(0.71, 1.24) | 0.81(0.60, 1.10) | 103 |
Cardiovascular disease | 2,377 | 1,105 | 0.91(0.84, 0.99) | 0.91(0.83, 0.99) | 1,272 |
Outcome | Total | Camp Lejeune # | Unadjusted HR (95% CI) | Adjusted HR (95% CI) | Camp Pendleton # |
Anemias | 10 | 7 | 2.38(0.61, 9.24) | 1.91(0.48, 7.65) | 3 |
Chronic liver disease | 87 | 36 | 0.64(0.42, 0.98) | 0.74(0.48, 1.15) | 51 |
Alcoholic liver disease | 49 | 16 | 0.43(0.24, 0.78) | 0.54(0.29, 1.00) | 33 |
Nonalcoholic liver disease | 36 | 19 | 1.04(0.54, 2.01) | 1.11(0.57, 2.17) | 17 |
Alcoholism | 17 | 7 | 0.63(0.24, 1.65) | 0.67(0.24, 1.83) | 10 |
Chronic kidney disease | 75 | 49 | 2.04(1.27, 3.29) | 1.88(1.13, 3.11) | 26 |
COPD | 384 | 171 | 0.86(0.70, 1.05) | 0.91(0.74, 1.12) | 213 |
Multiple sclerosis | 6 | 3 | 0.97(0.19, 4.80) | 0.83(0.16, 4.25) | 3 |
Amyotrophic Lateral Sclerosis | 15 | 5 | 0.50(0.17, 1.47) | 0.44(0.15, 1.34) | 10 |
Parkinson disease | 61 | 30 | 1.09(0.66, 1.80) | 1.21(0.72, 2.04) | 31 |
Suicide | 74 | 29 | 0.59(0.37, 0.94) | 0.72(0.45, 1.16) | 45 |
HR: hazard ratio |
CI: confidence interval |
CNS: Central nervous system cancers |
CLL: Chronic lymphcytic leukemia |
AML: Acute myeloid leukemia |
CML: Chronic myeloid leukemia |
COPD: Chronic obstructive pulmonary disease |
Totals: |
Camp Lejeune = 7,332 Females = 3,624 Males = 3,708 |
Camp Pendleton = 6,677 Females = 3,031 Males = 3,646 |
Causes of death that were not evaluated because the number of cases were < 2 for CL and/or CP: |
Testicular cancer |
Male breast cancer |
Thyroid cancer |
Acute lymphocytic leukemia |
HRs adjusted for sex, race, blue collar work (y/n) and education level; age was the time variable. |
The unadjusted and adjusted HRs from the Cox proportional hazards regressions for contributing causes of death comparing the Camp Lejeune versus Camp Pendleton civilian workers are shown in Supplemental file, Table S7). An adjusted HR ≥ 1.20 with CIR ≤ 3 was observed for female breast cancer (HR = 1.33, 95% CI: 0.87, 2.03). Other contributing causes of death with adjusted HRs ≥ 1.20 but with CIRs > 3 included cancers of the pharynx and larynx, melanoma, Hodgkin lymphoma, and CML.
Analysis of underlying causes of death and duration of employment at Camp Lejeune between October 1972 and December 1985 with Camp Pendleton as the referent group is shown in Supplemental file, Table S8. The categorical levels of duration were approximately tertiles of the data after removal of the reference group. Since the DMDC data is quarterly, the levels of the categorical variable consisted of the number of quarters the worker was employed at Camp Lejeune: “low” duration (1–5 quarters), “medium” duration (6–22 quarters), and “high” duration (≥ 23 quarters). A monotonic trend was observed for kidney cancer, with low duration HR of 1.36 (95% CI: 0.48, 3.82) and high duration HR of 1.68 (95% CI: 0.75, 3.76) and CIR > 3 across all durations.
The negative control diseases for alcohol consumption were alcoholism, alcoholic liver disease and chronic liver diseases. The negative control diseases for smoking were COPD and cardiovascular disease. In the analyses of underlying and contributing causes of death comparing Camp Lejeune and Camp Pendleton Marines/Navy personnel in the subgroup (Table 5; Supplemental file, Table S5), COPD as an underlying cause had an HR of 1.08 (95% CI: 0.93, 1.27) and CIR ≤ 3. All other negative control diseases for smoking and alcohol consumption had HRs < 1.00. In the analyses of underlying and contributing causes of death comparing Camp Lejeune and Camp Pendleton civilian workers (Table 6; Supplemental file, Table S7 ), COPD as a contributing cause had an HR of 1.04 (95% CI: 0.91, 1.20) and CIR ≤ 3. All other negative control diseases for smoking and alcohol consumption had HRs < 1.00.
The findings for the negative control diseases for alcohol consumption and smoking suggest that the prevalence of smoking and alcohol consumption were not greater at Camp Lejeune compared to Camp Pendleton. Even though the HRs for COPD were slightly greater than 1.00 for the Marines/Navy personnel and civilian workers, the cardiovascular disease HRs were < 1.00. Moreover, the HRs for all the negative control diseases for alcohol consumption were < 1.00. To evaluate the impact of possible confounding due to smoking and alcohol consumption, quantitative bias analyses were conducted using the results for COPD (smoking) and chronic liver disease (alcohol use).
To fully explain the HR for COPD of 1.08, the difference in smoking prevalence between Camp Lejeune and Camp Pendleton Marines/Navy personnel would be about 6%, assuming a range of RRs between 3.00 and 5.50 for smoking and COPD mortality [43] (Supplemental file, Figure S1). (Assuming a higher RR for smoking and COPD would decrease the difference in smoking prevalence between Camp Lejeune and Camp Pendleton and would therefore reduce the potential impact of confounding due to smoking in this study.) Assuming a 6% difference in smoking prevalence and a range of RRs for smoking and kidney cancer between 1.25 and 1.75 [44], the observed adjusted HR for kidney cancer of 1.21 would be reduced to between 1.17 and 1.18, a change of about 3.3% (Supplemental file, Figure S2). Assuming a range of RRs for smoking and esophageal cancer between 1.5 and 3.5 [44–45], the observed adjusted HR of 1.24 would be reduced to between 1.17 and 1.21, a change of no more than 5.6% (Supplemental file, Figure S3).
Smoking has been observed to decrease the risk of Parkinson disease [46]. Adjusting for smoking, the observed adjusted HR of 2.05 would increase to between 2.07 and 2.12, a change of no more than 3.4% (Supplemental file, Figure S4). Finally, since smoking is a strong risk factor for lung cancer, the impact of adjusting for smoking on the observed adjusted HR for lung cancer should be the greatest. Assuming a 6% prevalence difference in smoking and assuming that the RR for smoking and lung cancer ranges between 7.00 and 12.00 [44], the observed adjusted HR of 1.18 for lung cancer as an underlying cause would be reduced to between 1.07 and 1.08, a change of no more than 9.3% (Supplemental file, Figure S5).
For smoking to fully explain the HR for COPD of 1.04, the difference in smoking prevalence between the Camp Lejeune and Camp Pendleton civilian workers would be no more than 3% (Supplemental file, Figure S6). Adjusting for a smoking prevalence difference of 3% and assuming RRs for smoking and cancers of the lung and larynx ranging between 7.00 and 12.00 [44], the underlying cause HRs of 1.13 for lung cancer and 1.19 for laryngeal cancer would decrease no more than about 5.3% (Supplemental file, Figures S7 to S8). The HR for laryngeal cancer as a contributing cause of 1.69 would also decrease by no more than 5.3% (Supplemental file, Figure S9). The adjusted HR for cancer of the pharynx as an underlying cause would decrease from 2.21 to 2.10, assuming the RR for smoking and cancer of the pharynx ranges from 5.0 to 7.5 [44] (Supplemental file, Figure S10). Assuming RRs for smoking and kidney cancer and chronic kidney disease ranging from 1.30 to 1.80 [44, 47], the underlying cause HRs of 1.44 for kidney cancer and 1.88 chronic kidney disease would decrease by no more than about 2% (Supplemental file, Figures S11 to S12).
Adjusting for smoking and assuming RRs for smoking and Parkinson disease ranging between 0.40 and 0.90, the underlying cause HR for Parkinson disease of 1.21 would increase by no more than 2.5% (Supplemental file, Figure S13).
For the subgroup of Marines/Navy personnel, the adjusted HRs for chronic liver disease mortality as an underlying and contributing cause were 0.93 and 0.88, respectively. A recent systematic review of alcohol consumption and mortality due to liver cirrhosis found RRs of 2.65, 6.83 and 16.38 for drinking 25g/day (2 drinks/day), 50g/day (4 drinks/day) and 100g/day (8 drinks/day) compared to those who never drank alcoholic beverages [48]. A military survey conducted in 1980 found that about 30% of Marines were heavy drinkers defined as drinking five or more drinks per typical drinking occasion at least once a week in the past 30 days. [49].
To determine what prevalence differences in alcohol consumption between Camp Lejeune and Camp Pendleton Marines/Navy personnel would be necessary to fully explain the chronic liver disease mortality HRs of 0.93 and 0.88, a quantitative bias analysis was conducted assuming that at least 2/3 of Marines/Navy personnel at Camp Lejeune consumed ≥ 1 drink/day. It was also assumed that the RRs for alcohol consumption and chronic liver disease mortality ranged between 2.5 and 10 [48]. To fully explain the RRs of 0.93 and 0.88, the prevalence differences would range between 6% and 10% and between 11% and 16%, respectively (Supplemental file, Figures S14 to S15). (Assuming a lower percentage of Camp Lejeune drinkers would decrease the prevalence difference range, e.g., if only half the Marines/Navy personnel at Camp Lejeune were drinkers, then the percentage difference ranges would be 5% − 9% and 9% -15% for chronic liver disease mortality as underlying cause and as contributing cause, respectively.)
Adjusting for an alcohol prevalence difference of 10% between Camp Lejeune and Camp Pendleton Marines/Navy personnel, and assuming RRs for alcohol consumption and esophageal cancer ranging from 1.25 to 5.25 [50, 51], the HR of 1.24 for esophageal cancer as an underlying cause would increase to between 1.27 and 1.38 (Supplemental file, Figure S16). The HR of 1.14 for laryngeal cancer as a contributing cause would increase to between 1.15 and 1.23 (Supplemental file, Figure S17). The female breast cancer HR of 1.20 as an underlying cause would increase to between 1.21 and 1.26 (Supplemental file, Figure S18).
For the civilian workers, the adjusted HR for chronic liver disease mortality as an underlying cause was 0.74. To fully explain this HR, the prevalence difference in alcohol consumption between Camp Lejeune and Camp Pendleton workers would range between 15% and 25%, assuming that about 1/3 of the Camp Lejeune workers consumed ≥ 1 drink/day and assuming that the range of RRs for alcohol consumption and chronic liver disease mortality range between 2.5 and 10 (Supplemental file, Figure S19). (Assuming that only 20% of Camp Lejeune workers consumed ≥ 1 drink/day, the prevalence difference would range from 11–21%. Assuming a higher percentage of Camp Lejeune drinkers would increase the prevalence difference range, e.g., if 50% of Camp Lejeune workers consumed ≥ 1 drink/day, the prevalence difference would range from 21–31%.)
Adjusting for an alcohol prevalence difference of 15% between Camp Lejeune and Camp Pendleton workers, the HR of 1.12 for oral cancers as a contributing cause would increase to between 1.13 and 1.41; the HR of 1.19 for laryngeal cancer as an underlying cause would increase to between 1.20 and 1.40; the HR of 2.21 for pharyngeal cancer as an underlying cause would increase to between 2.24 and 2.79; and the HR of 1.19 for female breast cancer as an underlying cause would increase to between 1.20 and 1.27 (Supplemental file, Figures S20-S23).
The impact of non-differential exposure misclassification on the adjusted HRs for the Marines/Navy personnel and civilian workers assumed that between 10% and 25% of those assigned to Camp Lejeune were truly unexposed and virtually none of those assigned to Camp Pendleton were truly exposed (Supplemental file, Tables S9-S10).
For underlying cause of death in the Marines/Navy personnel subgroup, after accounting for exposure misclassification the observed adjusted HR for kidney cancer of 1.21 would increase to between 1.23 and 1.27, a change of no more than 5% (Supplemental file, Table S9). For esophageal cancer, the observed adjusted HR of 1.24 would increase to between 1.27 and 1.32, a change of no more than 6.5%. For Parkinson disease, the observed adjusted HR of 2.05 would increase to between 2.17 and 2.40, a change of no more than 17%. For lung cancer, the observed adjusted HR of 1.18 would increase to between 1.20 and 1.23, a change of no more than 4.2%.
For civilian workers, adjusting for non-differential exposure misclassification would increase the underlying cause HRs for lung cancer and female breast cancer by no more than about 3% (Supplemental file, Table S10). However, the underlying cause HR for kidney cancer would increase between 6.3% and 12.5%, and the underlying cause HR for chronic kidney disease would increase between 4.8% and 13.3%. The underlying cause HR for Parkinson disease would increase between 2.5% and 5% and the contributing cause HR for female breast cancer would increase between 2.3% and 6%.